Full-Time

Head of Sales

Posted on 9/27/2025

Weave

Weave

11-50 employees

Generative AI platform for life-science collaboration

Compensation Overview

$225k - $275k/yr

+ Equity

San Francisco, CA, USA

Hybrid

Hybrid role with flexibility for occasional remote work; based in San Francisco Bay Area.

Category
Sales & Account Management (2)
,
Requirements
  • 10+ years of SaaS sales experience with at least 5+ years in a sales leadership role
  • Demonstrated success managing enterprise sales teams selling into Life Sciences (biotech, pharma, CROs)
  • Proven track record of exceeding quarterly and annual bookings/revenue goals
  • Expertise in enterprise sales methodologies (e.g., MEDDICC, Challenger)
  • Strong leadership and coaching ability with excellent communication skills
  • Skilled in pipeline management, forecasting, and CRM optimization (HubSpot preferred)
  • Ability to engage with C-level executives and influence strategic decision-making
  • Bachelor's degree in Life Sciences, Business or a related field is required
  • Experience with SaaS or document management solutions is required
  • Documented sales management/leadership experience with teams managing business pipelines from identification to contract signing
  • Up to 30% travel for prospect/customer meetings, tradeshows and events
Responsibilities
  • Set territory sales goals, pipeline targets, and incentive structures aligned with new business growth objectives
  • Define and refine ideal customer profiles and target account strategies. Drive predictable revenue through accurate forecasting and disciplined pipeline management
  • Collaborate cross-functionally with Customer Success, Marketing, and Product to ensure GTM alignment and consistent value messaging
  • Lead by example on high-value enterprise deals and support the team in complex negotiations
  • Recruit, train, and develop a high-performing enterprise SaaS sales team
  • Coach new hires to ramp within one month of starting on the Weave team and support the ongoing training and development of the sales team
  • Establish week-over-week accountability for deal progression
  • Refine and scale the existing sales process; build a playbook for repeatability that anchors around optimized pipeline coverage, forecast accuracy, sales cycle length (velocity), win rate and quota attainment
  • Lead weekly pipeline reviews and quarterly business reviews, keeping performance-driven culture front and center
  • Optimize CRM usage (HubSpot) to ensure pipeline visibility, KPI tracking, and data integrity
  • Establish sales dashboards for internal use and leadership reporting
  • Monitor industry and competitive trends to inform pricing strategy and customer engagement models
  • Ensure compliance with procurement, contracting, and data security requirements in enterprise deals
Desired Qualifications
  • Knowledge of FDA, EMA, ICH guidelines, or other regulatory bodies is a plus
  • Previous exposure to the biotech, pharmaceutical, or clinical research industry is highly desirable
  • Up to 30% travel is desirable

Weave.bio provides a platform for life sciences collaboration by integrating a generative AI system with a knowledge graph to connect researchers, data, and projects. The platform generates insights and maps connections across datasets, research teams, and workflows, while an incentive system rewards contributors proportionally to the value they add. Unlike tools that focus on a single function, Weave.bio combines collaboration features with a data-linking graph and an explicit rewards model to reduce silos and encourage sharing. The goal is to accelerate biomedical research and development, helping pharma, biotech, and academic researchers move from discovery toward real-world impact faster.

Company Size

11-50

Company Stage

Series A

Total Funding

$31.6M

Headquarters

New Haven, Connecticut

Founded

2023

Simplify Jobs

Simplify's Take

What believers are saying

  • $20M Series A in October 2025 fuels global expansion and AI enhancements.
  • Strategic Advisory Board from Takeda and Gilead accelerates platform adoption.
  • Parexel partnership cuts NDA authoring time by over 60%.

What critics are saying

  • FDA's March 2026 guidance mandates human-only validation, blocking AutoIND features.
  • Rivanna Labs' May 2026 open-source RegAI Pro undercuts Weave's subscriptions.
  • EMA's July 2026 rules bar Weave from 35% of EU pipeline without on-premise deployment.

What makes Weave unique

  • Weave's AI-native platform automates full eCTD dossiers from IND to NDA authoring.
  • Built-in Data Room ensures traceability linking source data to submissions seamlessly.
  • Parexel-exclusive NDA templates leverage 40 years of regulatory expertise.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Weave who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

-2%
Business Wire
Mar 25th, 2026
Weave Bio forms strategic advisory board to guide AI-driven regulatory science evolution

Weave Bio, an AI-driven regulatory automation company, has established its inaugural Strategic Advisory Board to guide the development of its platform and advance AI adoption in life sciences regulation. The board comprises senior executives from pharmaceutical companies and academia, including leaders from Takeda, Boehringer Ingelheim, Gilead, Stanford University and Serrado Capital. The SAB formation follows significant momentum for the San Francisco-based startup, which raised $20 million in Series A funding in October 2025 and announced a strategic partnership with Parexel. Weave Bio's platform streamlines regulatory content preparation for pharmaceutical companies, reducing regulatory timelines by over 50 percent whilst maintaining FDA and EMA compliance standards. Founded in 2022, Weave Bio has raised backing from investors including USVP, Innovation Endeavors and Magnetic Ventures.

Business Wire
Oct 18th, 2025
Weave Bio Secures $20M Series A Funding to Enhance Its AI-Native Regulatory Platform

Weave Bio raises $20M Series A to expand its AI-native platform that accelerates regulatory workflows for drug development.

FinSMEs
Oct 17th, 2025
Weave Bio Raises $20M in Series A Funding

Weave Bio raises $20M in Series A funding. Weave Bio, a San Francisco, CA-based provider of AI-native regulatory automation management solutions, raised $20m in Series A funding. The round, which brought total capital raised to $36m, was led by USVP, with participation by Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. The company intends to use the funds to accelerate product development and expand its commercial team. In details, Weave Bio will: * complete its coverage of the entire regulatory lifecycle of therapeutics, inclusive of market applications (NDA/BLA), responses to health authority questions (HAQ/RTQ), and post-market updates and submissions; * Expand into global markets beyond the U.S. FDA, including Europe, Japan, and Latin America; and * Build advanced AI capabilities that will provide insights into therapeutic portfolios and empower strategic decision-making across the drug development process. Led by Brandon Rice, CEO and co-founder, Weave Bio provides an AI-native, cloud-based, software platform that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed.

FinanzNachrichten.de
Oct 16th, 2025
Weave Bio Secures $20M Series A Funding

Weave Bio has secured $20 million in Series A funding, led by USVP with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. This brings the company's total capital raised to $36 million. The funding will be used to enhance Weave's AI-native regulatory platform, expand global market reach, and build advanced AI capabilities. The platform aims to streamline regulatory workflows for pharmaceutical companies, biotech firms, and regulatory consultants.

Business Insider
Sep 30th, 2025
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes

Parexel announces AI partnership with Weave Bio to accelerate regulatory submission processes.

INACTIVE